IsoPlexis To Present New Collaboration Data at the American Society of Hematology Annual Meeting

BRANFORD, Conn., Dec. 4, 2017 /PRNewswire-USNewswire/ -- IsoPlexis Corporation (IsoPlexis), a privately held life science company at the forefront of single-cell analytics technology and the immune-based cancer treatment revolution, announced today that it will present new data from a collaboration with Bellicum Pharmaceuticals (Bellicum) at the American Society of Hematology's Annual Meeting and Exposition, held December 9-12, 2017, in Atlanta, Ga.

The presentation will highlight how IsoCode Chip, IsoPlexis' core technology developed to detect cellular responses at the single-cell level, was used to assess functional response to prostate stem cell antigen (PSCA) with Bellicum's proprietary GoCAR-T products targeting PSCA-expressing solid tumors.

The IsoCode Chip was used to assess Bellicum's CAR-T products with its novel "on" switch, and showed the ability for Bellicum's switch, inducible MyD88/CD40 (iMC), to increase the prevalence of on-target, antigen-specific polyfunctional CAR-T cells against solid tumor targets when activated by the dimerizing ligand rimiducid.

"IsoPlexis is excited to collaborate with Bellicum on this exciting research to push novel CAR-T therapies forward," said IsoPlexis Chief Executive Officer and Co-Founder Sean Mackay. "Using the IsoCode Chip, we're helping our partners use this polyfunctional T-cell data to target improved patient outcomes in difficult-to-treat cancers."

"The IsoPlexis technology helped advance the Bellicum product characterization process," said Dr. Aaron Foster, Ph.D., Bellicum Vice President of Product Discovery. "By characterizing our GoCAR-T products in a deeper functional fashion, we are able to show the ability to produce highly on-target functional reactions with our inducible costimulation platform." 

For additional information on this presentation, visit: https://ash.confex.com/ash/2017/webprogram/Paper105352.html.

IsoPlexis data will also be featured in a separate ASH presentation, "Identification of Functional Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy of Chronic Lymphocytic Leukemia." To read the full abstract, visit: https://ash.confex.com/ash/2017/webprogram/Paper105422.html.

ABOUT ISOPLEXIS:

IsoPlexis, a privately held life sciences company, is developing novel technologies at the forefront of the revolution in immunity-based treatments of cancer. Using a next-generation diagnostic and therapeutic platform to identify patient responses at the single-cell level, IsoPlexis' original scientific leaders from Yale, Caltech, UCLA, and Memorial Sloan Kettering Cancer Center have advanced understandings of personalized therapies against various cancers. IsoPlexis is venture funded by Spring Mountain Capital, North Sound Ventures, and Connecticut Innovations, as well as supported through grant funding from the National Cancer Institute and the National Institutes of Health. For additional information on IsoPlexis, visit http://www.isoplexis.com or email [email protected].

SOURCE IsoPlexis Corporation

Related Links

http://www.isoplexis.com